Adaptin Bio (APTN) Cash from Financing Activities (2023 - 2026)

Adaptin Bio has disclosed Cash from Financing Activities across 4 years of filings, most recently posting $819343.0 for Q2 2026.

• In Q2 2026, Cash from Financing Activities changed N/A year-over-year to $819343.0; the TTM figure through Jun 2026 stood at $1.8 million (down 63.08% YoY), while the FY2025 annual figure was $5.2 million, up 666.71% from the prior year.
• Cash from Financing Activities came in at $819343.0 for Q2 2026 at Adaptin Bio, up from $438433.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $4.6 million in Q1 2025 to a low of -$193876.0 in Q4 2024.
• Average Cash from Financing Activities over 4 years is $799746.4, with a median of $438433.0 recorded in 2026.
• Year-over-year, Cash from Financing Activities sank 432.28% in 2024 and jumped 5033.36% in 2025.
• Over 4 years, Cash from Financing Activities stood at $58347.0 in 2023, then slumped by 432.28% to -$193876.0 in 2024, then jumped by 400.69% to $582961.0 in 2025, then surged by 40.55% to $819343.0 in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were $819343.0 in Q2 2026, $438433.0 in Q1 2026, and $582961.0 in Q4 2025.